However, as immune checkpoint inhibitors including programmed cell death 1 (PD-1) antibody have shown encouraging results in HCC patients when in combination with other therapeutic agents [46, 47], the combination therapy of DEXP&A&N with anti-PD-1 antibody is warranted in future studies. Here, PDCD1 is linked to hepatocellular carcinoma.